Shamburg News · 8-K filed Oct 29, 2026, 4:05 PM EDT
Enanta Pharmaceuticals' EU patent suit against Pfizer over Paxlovid dismissed after UPC invalidity ruling
ENTA · ENANTA PHARMACEUTICALS INC
- Other event
- Materiality: medium
Enanta Pharmaceuticals, Inc. filed a patent infringement action in the Unified Patent Court against Pfizer Inc. and certain subsidiaries concerning European Patent No. EP 4 051 265 and Paxlovid sales in the 18 participating EU member states. Pfizer counterclaimed for revocation of the patent, and a hearing was held on September 29, 2026. On October 29, 2026, the UPC decided that the '265 Patent is invalid and that the infringement action was unfounded.
Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001193125-26-437774.
Written from the filing by Shamburg Markets. Figures are as reported by the company.